SOSultan Ozkurt

Sultan Ozkurt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sultan Ozkurt has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Ahmet Musmul

    Faculty of Medicine, Department of Biostatistics, Eskisehir Osmangazi University, Eskisehir, Turkey

    4 shared publications
  • Ahmet Ugur Yalcin

    Nephrology, Faculty of Medicine, Eskişehir Osmangazi Üniversitesi, Eskişehir, TUR

    4 shared publications
  • Ahmet Uğur Yalçın

    ESKİŞEHİR OSMANGAZİ ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, NEFROLOJİ BİLİM DALI

    3 shared publications
  • Ibrahim Dogan

    Department of Nephrology, Faculty of Medicine, Hitit University, Çorum, Turkey

    3 shared publications
  • Cigdem Mengus

    Eskisehir Osmangazi Univ, Fac Med, Dept Nephrol, Eskisehir, Turkey

    2 shared publications
  • Garip Sahin

    Division of Nephrology, Faculty of Medicine, Eskişehir Osmangazi University, 26480 Eskişehir, Türkiye

    2 shared publications

Latest Publications

  • C-Reactive Protein–Albumin–Lymphocyte Index, Prognostic Nutritional Index, and Glasgow Prognostic Score as Predictors of Acute Renal Allograft Rejection: A Comparative Analysis

    by Yavuz Selim Angın, Gökberk Alagaş, Akile Zengin, Cengiz Ceylan, Sultan Özkurt, Ahmet Uğur Yalçın, Garip Şahin, Rüya Mutluay, Murat Ulaş, Mehmet Kılıç

  • A Case of Unexpected Elevated Bilirubin Levels in Urine

    by Elif Nur Arıkan Bakım, Hüseyin Kayadibi, İ. Özkan Alataş, Sultan Özkurt, Yüksel Çavuşoğlu

    Tam idrar analizi diyabet, karaciğer veya üriner sistem hastalıkları, hidrasyon, idrar yolu enfeksiyonları ve birçok klinik durum hakkında önemli bilgiler sağladığı için klinisyenler tarafından sıklıkla istenir. Tam idrar analizi sonuçları diyet, gıda takviyeleri ve ilaç tedavileri dahil olmak üzere birçok faktörden etkilenebilir. Bu vaka sunumunda idrarda etodolak etken maddeli antienflamatuvar bir ilaç alımı kaynaklı yanlış pozitif idrar bilirubin vakası sunuldu.

  • From ulcerative colitis to amyloid storm: a case-based review

    by Sultan Özkurt, Döndü Üsküdar Cansu, Uygar Yildirim, Emel Yaldir, Ahmet Uğur Yalçin, Cengiz Korkmaz

    The most important complication of familial Mediterranean fever (FMF) are AA amyloidosis and amyloid nephropathy. Amyloid nephropathy typically follows a slow, indolent course. However, "amyloid storm" is a recently described acute condition, characterized by sudden onset of severe proteinuria and rapidly progressive renal failure with markedly acute-phase reactants, progressing over days to weeks into end-stage renal disease (ESRD). Amyloid storm has been rarely reported in the literature. Most cases have occurred in patients with known FMF-related AA amyloid nephropathy. However, it has also been reported as the initial presentation of AA amyloidosis. No standardized treatment guidelines exist, but management has included supportive care, colchicine, and interleukin (IL)-1 blockade. This report presents the first case of amyloid storm associated with ulcerative colitis in the literature. The patient exhibited impaired oral intake and fatigue, alongside acute kidney injury, spot urine proteinuria of approximately 100 g/day, and elevated C-reactive protein levels (CRP 118 mg/L). The diagnosis of AA amyloidosis was made after a kidney biopsy. In addition to starting haemodialysis, the patient was treated with anakinra and colchicine given the clinical presentation indicative of an amyloid storm. Subsequently, the acute-phase reactants decreased and the patient's general health improved, but haemodialysis was still required. After the patient discontinued anakinra treatment, he was re-hospitalized with complaints of fatigue and weakness but died on day 71 after the amyloid storm diagnosis. In our literature review, we identified a total of 36 patients with amyloid storm, 29 of whom were from two separate original studies. According to our review, the frequency of FMF-associated amyloid storm is 5.5%. The majority of patients were male, and while FMF was the most common cause of AA amyloidosis, ankylosing spondylitis, non-FMF autoinflammatory diseases, and ulcerative colitis were among the other causes. Our analysis revealed that infections were the most common triggering factor of an amyloid storm. ESRD rates were found to be up to 67%, and mortality rates ranged from 33 to 67%. This case report aims to highlight the relatively new and little-known concept of amyloid storm, which, despite its rarity, discusses its clinical features, laboratory findings, treatment options, and outcomes based on our case as well as a few cases in the literature.

  • Open Access

    Post-Earthquake Realities: A Study on the Challenges of Relocated Hemodialysis Patients Following the Kahramanmaraş Earthquake

    by Murat Tuğcu, Mustafa Keleş, Murat Duranay, Bülent Hüddam, Raziye Yazıcı, Yavuz Ayar, Fatma Betül Güzel, Zehra Eren, Sultan Özkurt, Ebru Gök Oğuz, et al.

    Background: In February 2023, Türkiye experienced 2 significant earthquakes, measuring 7.4 and 7.3 on the Richter scale and impacting 11 provinces. This study was performed to investigate the experiences of patients undergoing hemodialysis treatment in earthquake-affected areas who were relocated to alternative centers, with a focus on assessing the medical challenges that emerged thereafter. Methods: This study included 181 hemodialysis patients (71 females, 110 males) from 11 earthquake-affected provinces who were transferred to different dialysis centers because of infrastructure and superstructure damage at their original treatment facilities. Results: The predominant reason for relocation was damage to personal residences, reported by 77.4% of patients. Notably, 59.4% resumed hemodialysis with a delay of at least 1 day. Emergency complications were observed in 24.6% of patients, with hypervolemia (11.7%) being the most common. At the time of reporting, 23.1% of patients continued treat ment at the relocated centers, while 78.8% expressed intent to return to their original facilities. Importantly, only 1 patient was reported to have died during the study period, highlighting the overall resilience of this population. Conclusion: Hemodialysis patients are particularly vulnerable to the impacts of earthquake-related disruptions. Dialysis centers in high-risk regions must adhere to construction standards that ensure operational resilience. Additionally, priori tizing the transfer and medical coordination of hemodialysis patients during disasters is essential to maintaining continuity of care and minimizing health risks. Cite this article as: Tuğcu M, Keleş M, Duranay M, et al. Post-earthquake realities: A study on the challenges of relocated hemodialysis patients following the Kahramanmaraş earthquake. Turk J Nephrol. 2025;34(4):289-296.


  • Open Access

    Assessment of Renal Function of Bodybuilders Using Anabolic Androgenic Steroids and Diet Supplements

    by Sultan Ozkurt, Engin Ozakin, Hilal Gungor, Ahmet Ugur Yalcin

    Introduction Anabolic androgenic steroids (AAS) and diet supplements (DS) are frequently used by bodybuilders. In this specific group, increased muscle mass, the acute effects of exercise, and the use of creatine may affect the creatinine-based estimated glomerular filtration rate (eGFRcr), potentially leading to an underestimation of the GFR. Cystatin C equations offer a more accurate prediction of GFR that is independent of muscle mass. We aimed to assess the renal functions of bodybuilders who use both AAS+DS, as well as those who only use DS, by calculating the GFR based on cystatin C (eGFRcys) and also using a combination of cystatin C and creatinine (eGFRcys/cr). Methods The study included 12 bodybuilders using AAS+DS and 12 bodybuilders using DS. In both groups, serum cystatin C levels, eGFRcys, eGFRcys/cr, urine albumin excretion rates, urine protein excretion rates, and routine tests were examined. Results In AAS+DS users, the average duration of AAS use was 3.08±2.02 years, while for DS users, the duration of supplement use was 3.67±2.49 years. The spot urine albumin/creatinine and protein/creatinine ratios were higher in AAS+DS users (p<0.001 and p=0.006, respectively). Although eGFRcr was found to be similar in the AAS+DS and DS groups (119.67 ± 24.12 ml/min and 122.08 ± 18.03 ml/min, respectively; p=0.426), eGFRcys and the eGFRcys/cr ratio were significantly lower in the AAS+DS group compared to the DS group (eGFRcys: 120.67 ± 19.48 ml/min vs. 122.08 ± 18.03 ml/min, p=0.039; eGFRcys/cr: 121.83 ± 20.62 ml/min vs. 126.33 ± 21.163 ml/min, p= 0.036, respectively). Conclusion Cystatin-based GFR values were found to be significantly lower in AAS+DS users, and urinary albumin and protein excretion were considerably higher compared to DS users. Although these findings suggest a potential link between early kidney damage and the direct use of AAS, the topic requires further investigation.


  • Open Access

    Evaluation of hemodialysis patients and hemodialysis health workers with COVID-19 IgM and IgG antibody test; a multicenter study from Eskisehir, Turkey

    by Sultan Ozkurt, Neslihan Tezcan, Cigdem Mengus, Bulent Ozgur, Ozge Alkan Tali, Emcet Saidoglu, Hulya Ozarkan, Handan Golgeli, Mehmet Erol, Muzaffer Bilgin, et al.

    OBJECTIVE: Hemodialysis (HD) patients are a population at high risk for exposure to the severe respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Undiagnosed mild or asymptomatic SARS-CoV-2 infection in HD patients can make these patients a potential source of infection. In our study, we aimed to evaluate the entire spectrum of SARS-CoV-2 infection with the IG M and IG G rapid antibody kit in HD patients and healthcare providers working in HD unit.METHODS: 633 HD patients and 134 health workers from all dialysis centers (three private and three public) in Eskisehir were included in the study. Blood samples obtained from participants were allowed to clot for 30 min at room temperature at 15 degrees C using a serum separator tube. Then it was centrifuged at 1000 g at 2-8 degrees C for 15 min. The supernatant was collected and the samples were stored at -20 degrees C until use. Serum samples stored at the end of the study were studied with the A.B.T.TM Biotechnology COVID-19 Rapid IgG-IgM Diagnostic Test. Routine examination was measured by standard methods. All participants were evaluated by serological analysis of IgG and IgM antibodies against the SARS-CoV-2 recombinant antigen.RESULTS: Two symptomatic HD patients (0.27%) were diagnosed with SARS-CoV-2 infection by real-time reverse-transcription-polymerase-chain - reaction test and chest tomography. In 15 (2.36%) of 633 asymptomatic patients, antibody was positive against the SARS-CoV recombinant antigen (IgG in 13, both IgG and IgM in 2), while no antibodies were detected in 134 health workers.CONCLUSION: We have shown that most HD patients with SARS-CoV-2 experience the disease asymptomatically, and that antibody testing plays an important role in identifying patients with asymptomatic infection.

  • Open Access

    Fibromyalgia syndrome and related factors in hemodialysis, peritoneal dialysis, and renal transplant patients: A cross-sectional study

    by Ayla Çağlıyan Türk, Sultan Özkurt, İbrahim Doğan, Füsun Şahin

    Objectives: This study aims to investigate the point prevalence of fibromyalgia in patients on hemodialysis and peritoneal dialysis and after renal transplantation compared to healthy controls and to evaluate depressive symptoms, anxiety level, and the impact of fibromyalgia on quality of life (QoL). Patients and methods: Between January 2018 and January 2019, a total of 107 hemodialysis patients (Group 1) (48 males, 59 females; median age: 50 years; range, 42 to 56 years), 51 peritoneal dialysis patients (Group 2) (32 males, 19 females; median age: 49 years; range, 39 to 54 years), 52 renal transplant patients (Group 3) (23 males, 29 females; median age: 45.5 years; range, 37 to 52 years), and 50 healthy controls (Group 4) (23 males, 27 females; median age: 46.5 years; range, 42 to 50 years) were included in the study. Age, sex, amount of time spent on dialysis, and laboratory data were recorded. Impact of fibromyalgia on QoL was evaluated using the Fibromyalgia Impact Questionnaire (FIQ), while depressive symptoms and anxiety level were assessed using the Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI), respectively. Results: The point prevalence of fibromyalgia was 14% in Group 1 (n=15), 5.9% in Group 2 (n=3), 9.6% in Group 3 (n=5), and 4% in Group 4. There was a significant difference in the point prevalence of fibromyalgia between the hemodialysis group and healthy controls (p


  • Assessment of Ischemia Modified Albumin as a Marker of Oxidative Stress in Chronic Kidney Disease

    by Sultan Ozkurt, Oguzhan Ozcan, Ibrahim Dogan

    Increased oxidative stress (OS) in chronic kidney disease (CKD), and particularly in those undergoing hemodialysis (HD), is widely recognized. We aimed to evaluate ischemia modified albumin (IMA) as a marker of OS in CKD patients who are not yet on HD compared to chronic HD patients. A cross-sectional study was conducted in Hitit University, Corum, Turkey in 2015. In this study, 39 chronic HD and 36 CKD patients in stage 3–4 were included, as well as 34 healthy individuals as a control group. IMA levels in HD patients (before and after HD session), stage 3-4 CKD patients and control group were evaluated using the ELISA method. Pre-HD and post-HD albumin levels were measured and albumin-adjusted IMA (aIMA) levels were calculated. IMA and aIMA levels were higher in chronic HD and CKD patients who are not yet on HD, compared to healthy individuals (IMA, 179.76 ± 60.46, 209.67 ± 69.84, 67.41 ± 32.22, P P P P P <0.001). CKD is associated with increased OS and the HD procedure itself also contributes to the increase in OS. IMA may serve as a feasible biomarker for determination of OS.


  • Open Access

    Does erythropoietin therapy affect circulating endothelial cells in hemodialysis patients?

    by T. Bulduk, A. U. Yalcin, O. M. Akay, S. G. Ozkurt, H. U. Teke, G. Sahin, G. Temiz, G. Demirel

    Anemia is a common complication of chronic kidney disease (CKD). The most common cause of anemia in CKD is erythropoietin deficiency; and the most important cause of mortality in CKD patients is atherosclerotic vascular complications which are associated with endothelial damage. One of the methods evaluating vascular integrity is the cytometric measurement of circulating endothelial cells and endothelial progenitor cells in peripheral blood. The study aimed to investigate the effects of erythropoietin therapy on endothelial dysfunction by evaluating circulating endothelial cells and endothelial progenitor cells in peripheral blood using the technique of flow cytometry. Methods. A total of 55 hemodialysis patients were evaluated in three groups; those having erythropoietin therapy for at least last 3 months (n = 20) / not having erythropoietin for at least the last 3 months (n = 20) and the patients who started erythropoietin treatment during the study (n = 5). The control group consisted of 20 people. Blood values of the 3rd Group were investigated three times as baseline, 2nd week and 8th week CD34 +, CD105 + cells were evaluated as activated circulating endothelial cells; CD133 +, CD146 + cells were evaluated as activated endothelial progenitor cells. Results. There was no difference between the patients and healthy individuals in terms of circulating endothelial cells and endothelial progenitor cells. In the third group, no differences were observed in circulating endothelial cells / endothelial progenitor cell levels at baseline / 2nd and 8th weeks. There was no correlation between erythropoietin and circulating endothelial cells / endothelial progenitor cells. Conclusion. A correlation is not available between the therapeutic doses of erythropoietin used in hemodialysis patients and circulating endothelial cells / endothelial progenitor cell levels; supratherapeutic doses could change the results.

  • Open Access

    Pain Assessment in Hemodialysis Patients

    by Esmira Sadigova, Ahmetugur Yalcin, Sultan Ozkurt

    Pain is a common complaint among hemodialysis (HD) patients; however, most patients are not assessed for this aspect and are not sufficiently treated. In these patients, pain is reported to be associated with a range of parameters like increased depression and disrupted quality of life (QOL). Previously residual renal function (RRF) was not assessed for associations with pain. The primary aim of the study is to evaluate the pain frequency in the Turkish HD patient population. In addition, the type, origin, and severity of chronic pain, the pain treatment ratio, and the relationship between pain, QOL, and RRF were investigated during the study. This study included 328 HD patients. Pain assessment used the McGill Pain Questionnaire and neuropathic pain assessment used the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scale. The correlation of pain and quality of life was evaluated with the Short Form 36 (SF-36) quality of life scale. Of patients, 244 experienced pain (74.4%), and this pain had a neuropathic character in 61.8% of these patients. Patients with pain had a longer dialysis duration than those without pain (4.00 (2.00-8.00), 3.00 (2.00-4.75), p=0.01). The most common site of pain was the lower extremities. Pain was observed more often among females and with increasing age. Only 36.4% of patients used analgesics. The quality of life of patients with pain was found to be lower. The incidence of pain was higher among patients without RRF and had more neuropathic character. Pain is a significant problem for the majority of HD patients and is not effectively managed. To increase the quality of life of patients, the care team should regularly question pain symptoms, and it should be treated effectively. In this context, RRF should be regularly monitored and efforts should be made to preserve it.